Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Roche's investment in startup Regor Therapeutics for a new breast cancer drug, worth $850 million, shows their commitment to innovative research. Prime's focus on gene editing research and partnership with Bristol Myers signifies the evolving landscape of biopharma collaborations. Aktis raising $175 million for radiopharma drug development, with support from investors like Bristol Myers, Eli Lilly, and Merck & Co., highlights the growing interest in this area. Bristol Myers' plans to sell a groundbreaking schizophrenia drug face potential challenges due to insurance barriers, impacting patient access. The newsletter covers blood-based biomarkers for Alzheimer's, company updates, and upcoming industry events, providing valuable insights into biopharma trends.Roche's acquisition of a CDK inhibitor from Regor for $850 million bolsters their breast cancer portfolio, as announced during Roche's pharma day presentation. J&J's positive Phase III results for Carvykti and Darzalex Faspro in multiple myeloma trials, along with Novartis' successful Lutathera radiopharma therapy for difficult-to-treat brain tumors, demonstrate significant advancements in cancer treatment. The FDA rejection of Lykos Therapeutics' PTSD therapy underscores the challenges in developing psychiatric disease therapies. WBL's new cfdna methylation assay aims to improve data quality in cfdna sequencing, enhancing research capabilities. Potential risks to women's health research and recent layoffs at companies like Inventprise raise concerns in the industry. Stay updated on upcoming events and job opportunities in the pharmaceutical sector.The phase 3 trial failure of Bristol Myers Squibb and 2seventy Bio's CAR-T cell therapy, Abecma, due to low enrollment emphasizes the importance of patient participation in clinical trials. The shift towards off-the-shelf CAR-T cell therapy approval by the FDA in January marks a significant milestone for drug developers like Atara Biosciences. Bristol Myers Squibb's new schizophrenia drug, Cobenfy, and the growing role of gene therapies in pharmaceutical manufacturing operations reflect the ongoing advancements in biopharma. Pharmavoice continues to deliver essential insights and perspectives in the life sciences industry.Stay informed with Pharma and Biotech daily for all the latest updates in the world of pharmaceuticals and biotechnology.